MiR-331-3p activates Wnt/β-catenin through the suppressor of tumorigenicity 7 protein-like (ST7L) and promotes resistance to chemotherapeutic drugs in prostate cancer [99]. This evidence concerns the gene ST7L and prostate carcinoma.